Spectrum and clinical manifestations of mutations in genes responsible for hypertrophic cardiomyopathy

被引:23
作者
Curila, Karol [1 ,2 ]
Benesova, Lucie [3 ]
Penicka, Martin [2 ]
Minarik, Marek [3 ]
Zemanek, David [4 ]
Veselka, Josef [4 ]
Widimsky, Petr [2 ]
Gregor, Pavel [2 ]
机构
[1] Charles Univ Prague, Dept Cardiol, Med Sch 3, Cardioctr,Fac Med 3, Prague 10034, Czech Republic
[2] Univ Hosp Kralovske Vinohrady, Prague 10034, Czech Republic
[3] Genomac Int, Lab Mol Genet & Oncol, Prague, Czech Republic
[4] Fac Hosp Motol, Ctr Cardiovasc, Prague, Czech Republic
关键词
Hypertrophic cardiomyopathy; gene; mutation; phenotype; BINDING PROTEIN-C; COMPOUND;
D O I
10.1080/AC.67.1.2146562
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Hypertrophic cardiomyopathy (HCM) is a cardiovascular disease with autosomal dominant inheritance. It is caused by mutations in the genes coding for structural and/or regulatory proteins found in the sarcomere of cardiomyocytes. A group of genes, including the heavy chain of beta-myosin (MYH7), myosin binding protein C (MYBPC3), cardiac troponin I (TNNI3) and cardiac troponin T (TNNT2) are frequently affected by causal mutations. While exact mutation frequency data has been obtained for various populations, no screening has been reported for Central European populations. Patients and methods We performed a complete sequencing of MYH7, MYBPC3,TNNI3 and TNNT2 genes in 100 HCM patients. Results We discovered mutations in a total of 40 patients (40%), including 4 patients with double mutations. A total of 35 different mutation types were detected, of which 17 were novel. The contributions from individual genes were: 24 mutations in MYBPC3 (54.5%), 14 in MYH7 (31.8%), 4 in TNNI3 (9%) and 2 mutations in TNNT2 (4.5%). We have observed a wide variability in disease manifestation across the different genes/mutation types. In addition, we have discovered differences in both frequency and distribution of mutations of the two most common genes (MYBPC3 and MYH7) compared to other populations. Conclusion The most common gene responsible for HCM in our study population was MYBPC3, followed by MYH7,TNNI3 and TNNT2. Phenotypic heterogeneity, as well as the dissimilarity to other populations, prevents effective use of a pre-screening test, which would be directed at the most common mutation hotspots, in our population.
引用
收藏
页码:23 / 29
页数:7
相关论文
共 19 条
[1]   Genetic testing for risk stratification in hypertrophic cardiomyopathy and long QT syndrome: fact or fiction? [J].
Ackerman, MJ .
CURRENT OPINION IN CARDIOLOGY, 2005, 20 (03) :175-181
[2]   Low Prevalence and Variable Clinical Presentation of Troponin I and Troponin T Gene Mutations in Hypertrophic Cardiomyopathy [J].
Curila, Karol ;
Benesova, Lucie ;
Penicka, Martin ;
Minarik, Marek ;
Zemanek, David ;
Veselka, Josef ;
Widimsky, Petr ;
Gregor, Pavel .
GENETIC TESTING AND MOLECULAR BIOMARKERS, 2009, 13 (05) :647-650
[3]   FAMILIAL HYPERTROPHIC CARDIOMYOPATHY - MICROSATELLITE HAPLOTYPING AND IDENTIFICATION OF A HOT-SPOT FOR MUTATIONS IN THE BETA-MYOSIN HEAVY-CHAIN GENE [J].
DAUSSE, E ;
KOMAJDA, M ;
FETLER, L ;
DUBOURG, O ;
DUFOUR, C ;
CARRIER, L ;
WISNEWSKY, C ;
BERCOVICI, J ;
HENGSTENBERG, C ;
ALMAHDAWI, S ;
ISNARD, R ;
HAGEGE, A ;
BOUHOUR, JB ;
DESNOS, M ;
BECKMANN, J ;
WEISSENBACH, J ;
SCHWARTZ, K ;
GUICHENEY, P .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2807-2813
[4]   Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy [J].
Erdmann, J ;
Daehmlow, S ;
Wischke, S ;
Senyuva, M ;
Werner, U ;
Raible, J ;
Tanis, N ;
Dyachenko, S ;
Hummel, M ;
Hetzer, R ;
Regitz-, V .
CLINICAL GENETICS, 2003, 64 (04) :339-349
[5]   Mutations in Sarcomeric Genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in Patients With Hypertrophic Cardiomyopathy [J].
Garcia-Castro, Monica ;
Coto, Eliecer ;
Reguero, Julian R. ;
Berrazueta, Jose R. ;
Alvarez, Victoria ;
Alonso, Belen ;
Sainz, Rocio ;
Martin, Maria ;
Moris, Cesar .
REVISTA ESPANOLA DE CARDIOLOGIA, 2009, 62 (01) :48-56
[6]  
Gregor P, 1992, PRAHA SCI MED, V260, P56
[7]   Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline [J].
Hershberger, Ray E. ;
Lindenfeld, Joann ;
Mestroni, Luisa ;
Seidman, Christine E. ;
Taylor, Matthew R. G. ;
Towbin, Jeffrey A. .
JOURNAL OF CARDIAC FAILURE, 2009, 15 (02) :83-97
[8]   Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling [J].
Ingles, J ;
Doolan, A ;
Chiu, C ;
Seidman, J ;
Seidman, C ;
Semsarian, C .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (10)
[9]   Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression [J].
Keren, Andre ;
Syrris, Petros ;
McKenna, William J. .
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2008, 5 (03) :158-168
[10]   Analysis of three major sarcomeric genes (MYH7, TNNT2, MYBPC3) in cardiomyopathy [J].
Maeda, Kazuho ;
Nakamura, Shigeki ;
Murakami, Chikako ;
Kobayashi, Masamune ;
Irie, Wataru ;
Wada, Bunta ;
Hayashi, Maiko ;
Sasaki, Chizuko ;
Furukawa, Masataka ;
Kurihara, Katsuyoshi .
FORENSIC SCIENCE INTERNATIONAL GENETICS SUPPLEMENT SERIES, 2009, 2 (01) :499-500